Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of MDX2003 in relapsed, progressive, or refractory B-cell malignancies
MOH_2026-02-24_015688Phase 2Not yet recruiting
- Sponsor
- ModeX Therapeutics
- Start
- Feb 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of MDX2003 in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and 3 more (2 arms), sponsored by ModeX Therapeutics. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
MDX2003
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)transformed B-cell lymphoma
Beyond the preview
Go deeper on MOH_2026-02-24_015688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-02-24_015688.